KEAP1 and neoplasm: The co-occurrence of KEAP1 and KRAS mutations suggests that KEAP1 mutations either affect NRF2 activity differently than KRAS-stimulated overexpression of NRF2, or are affecting other signalling pathways that are beneficial to the tumour.